These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 26377940

  • 1. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
    Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G.
    Cancer Res; 2015 Oct 01; 75(19):4086-96. PubMed ID: 26377940
    [Abstract] [Full Text] [Related]

  • 2. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
    Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ, Montgomery CP, Poulsom R, Harris AL.
    Cancer Res; 2011 Sep 15; 71(18):6073-83. PubMed ID: 21803743
    [Abstract] [Full Text] [Related]

  • 3. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
    Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R.
    PLoS One; 2014 Sep 15; 9(11):e112371. PubMed ID: 25393540
    [Abstract] [Full Text] [Related]

  • 4. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
    Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, Harris AL.
    Cancer Res; 2007 Dec 01; 67(23):11244-53. PubMed ID: 18056450
    [Abstract] [Full Text] [Related]

  • 5. Synaptojanin-2 binding protein stabilizes the Notch ligands DLL1 and DLL4 and inhibits sprouting angiogenesis.
    Adam MG, Berger C, Feldner A, Yang WJ, Wüstehube-Lausch J, Herberich SE, Pinder M, Gesierich S, Hammes HP, Augustin HG, Fischer A.
    Circ Res; 2013 Nov 08; 113(11):1206-18. PubMed ID: 24025447
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR, Guan YY, Luan X, Lu Q, Wang C, Liu HJ, Gao YG, Yang SC, Dong X, Chen HZ, Fang C.
    Biomaterials; 2015 Feb 08; 42():161-71. PubMed ID: 25542804
    [Abstract] [Full Text] [Related]

  • 8. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
    Lee D, Kim D, Choi YB, Kang K, Sung ES, Ahn JH, Goo J, Yeom DH, Jang HS, Moon KD, Lee SH, You WK.
    MAbs; 2016 Jul 08; 8(5):892-904. PubMed ID: 27049350
    [Abstract] [Full Text] [Related]

  • 9. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
    Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, Satyal S, Wang X, Clarke MF, Lewicki J, Gurney A.
    Cell Stem Cell; 2009 Aug 07; 5(2):168-77. PubMed ID: 19664991
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Delta-like ligand 4-notch blockade and tumor radiation response.
    Liu SK, Bham SA, Fokas E, Beech J, Im J, Cho S, Harris AL, Muschel RJ.
    J Natl Cancer Inst; 2011 Dec 07; 103(23):1778-98. PubMed ID: 22010178
    [Abstract] [Full Text] [Related]

  • 12. DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice.
    Minuzzo S, Agnusdei V, Pusceddu I, Pinazza M, Moserle L, Masiero M, Rossi E, Crescenzi M, Hoey T, Ponzoni M, Amadori A, Indraccolo S.
    Carcinogenesis; 2015 Jan 07; 36(1):115-21. PubMed ID: 25355291
    [Abstract] [Full Text] [Related]

  • 13. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T.
    Cancer Res; 2011 Mar 01; 71(5):1520-5. PubMed ID: 21193546
    [Abstract] [Full Text] [Related]

  • 14. Delta-like 4/Notch signaling and its therapeutic implications.
    Yan M, Plowman GD.
    Clin Cancer Res; 2007 Dec 15; 13(24):7243-6. PubMed ID: 18094402
    [Abstract] [Full Text] [Related]

  • 15. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.
    Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, Eberlein C, Kendrew J, Petteruti P, Cho S, Damschroder M, Peng L, Baker D, Smith NR, Weir HM, Blakey DC, Bedian V, Barry ST.
    Mol Cancer Ther; 2012 Aug 15; 11(8):1650-60. PubMed ID: 22679110
    [Abstract] [Full Text] [Related]

  • 16. The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.
    Zhou R, Wang S, Wen H, Wang M, Wu M.
    Exp Cell Res; 2019 Jul 15; 380(2):141-148. PubMed ID: 31034805
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer.
    Oishi H, Sunamura M, Egawa S, Motoi F, Unno M, Furukawa T, Habib NA, Yagita H.
    Pancreas; 2010 Aug 15; 39(6):897-903. PubMed ID: 20182391
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
    Kim DH, Lee S, Kang HG, Park HW, Lee HW, Kim D, Yoem DH, Ahn JH, Ha E, You WK, Lee SH, Kim SJ, Chun KH.
    BMB Rep; 2020 Nov 15; 53(10):533-538. PubMed ID: 32580836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.